First day Affordable Care Act (ACA) enrollment surpassed numbers from last year; CVS will offer next-day and same-day prescription delivery in 2018; and voter confusion surrounds Ohio's drug-pricing ballot measure.
In the first few days of open enrollment for the Affordable Care Act (ACA), numbers of people enrolling in coverage have surpassed the previous year. On the first day, more than 200,000 Americans chose a plan, which is more than double the number who signed up on day 1 in 2016, reported The Washington Post. Despite the White House reducing funding for promoting the ACA, traffic to HealthCare.gov was up 33% over last year. State exchanges are reporting similar increases. For example, Colorado reported more than 4000 people logged into the exchange, far surpassing the expected 2700.
With Amazon’s potential entry hanging over the pharmacy industry, CVS has announced a new strategy to offer next-day delivery of prescription drugs in 2018. In some big cities, CVS will offer same-day service, according to The New York Times. The announcement also follows falling retail sales, including prescription sales. At this time, the delivery partner for CVS has not yet been announced.
Ads around Ohio’s Drug Price Relief Act has muddied the waters and caused confusion for voters, who will need to weigh in on the single ballot-box question next week. According to Kaiser Health News, the act is supposed to combat rising drug costs, and the issue has gotten a lot of attention. Opponents and supporters have spent $58 million and $14 million, respectively. A similar measure was rejected in California last year.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More